These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 32304999)

  • 1. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
    Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B
    EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.
    Spina V; Bruscaggin A; Cuccaro A; Martini M; Di Trani M; Forestieri G; Manzoni M; Condoluci A; Arribas A; Terzi-Di-Bergamo L; Locatelli SL; Cupelli E; Ceriani L; Moccia AA; Stathis A; Nassi L; Deambrogi C; Diop F; Guidetti F; Cocomazzi A; Annunziata S; Rufini V; Giordano A; Neri A; Boldorini R; Gerber B; Bertoni F; Ghielmini M; Stüssi G; Santoro A; Cavalli F; Zucca E; Larocca LM; Gaidano G; Hohaus S; Carlo-Stella C; Rossi D
    Blood; 2018 May; 131(22):2413-2425. PubMed ID: 29449275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
    Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Zeng S; Zhang Q; Hu J; Zhou H; Xiong Y; Liu P
    Lancet Haematol; 2019 Jan; 6(1):e12-e19. PubMed ID: 30612710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
    Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
    Calabretta E; di Trani M; Corrado F; Sollini M; Cristaldi V; Marino F; Terzi di Bergamo L; Bruscaggin A; Pirosa MC; Bramanti S; Chiti A; Rossi D; Carlo-Stella C
    Br J Haematol; 2024 Feb; 204(2):514-524. PubMed ID: 37853658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.
    Wang D; Zhang J; Bu C; Liu G; Guo G; Zhang Z; Lv G; Sheng Z; Yan Z; Gao Y; Wang M; Liu G; Zhao R; Li T; Ma C; Bu X
    J Cancer Res Clin Oncol; 2024 Oct; 150(10):466. PubMed ID: 39422764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.
    Camus V; Viennot M; Lequesne J; Viailly PJ; Bohers E; Bessi L; Marcq B; Etancelin P; Dubois S; Picquenot JM; Veresezan EL; Cornic M; Burel L; Loret J; Becker S; Decazes P; Lenain P; Lepretre S; Lemasle E; Lanic H; Ménard AL; Contentin N; Tilly H; Stamatoullas A; Jardin F
    Haematologica; 2021 Jan; 106(1):154-162. PubMed ID: 32079702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer.
    Jiang R; Cheng X; Li P; Meng E; Wu X; Wu H
    Sci Rep; 2024 Jun; 14(1):14027. PubMed ID: 38890392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
    Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
    Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA in Hodgkin lymphoma.
    Maco M; Kupcova K; Herman V; Ondeckova I; Kozak T; Mocikova H; Havranek O;
    Ann Hematol; 2022 Nov; 101(11):2393-2403. PubMed ID: 36074181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy.
    Araujo DV; Wang A; Torti D; Leon A; Marsh K; McCarthy A; Berman H; Spreafico A; Hansen AR; Razak AA; Bedard PL; Wang L; Plackmann E; Chow H; Bao H; Wu X; Pugh TJ; Siu LL
    JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34056539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors.
    Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
    Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors.
    Jin Y; Chen DL; Wang F; Yang CP; Chen XX; You JQ; Huang JS; Shao Y; Zhu DQ; Ouyang YM; Luo HY; Wang ZQ; Wang FH; Li YH; Xu RH; Zhang DS
    Mol Cancer; 2020 Oct; 19(1):154. PubMed ID: 33126883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
    Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
    Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.
    Chi Y; Su M; Zhou D; Zheng F; Zhang B; Qiang L; Ren G; Song L; Bu B; Fang S; Yu B; Zhou J; Yu J; Li H
    Elife; 2023 Nov; 12():. PubMed ID: 37929934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
    Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
    Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.
    Yan Z; Ma J; Yao S; Yao Z; Wang H; Chu J; Zhao S; Liu Y
    Front Immunol; 2021; 12():727464. PubMed ID: 34899689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.